BD and Check-Points attains CE Mark for next-generation molecular screening test

BD (Becton, Dickinson and Company), global medical technology company, along with Check-Points Health B.V., affirmed that the companies sought CE Mark for a next-generation molecular screening test for antibiotic-resistant carbapenemase-producing organisms  on the fully-automated BD MAX System.

Reports hint that by 2050, an approximate of 10 million people could die annually from antimicrobial resistance if no action is taken. AMR is the ability of the microorganism to survive despite being treated with antimicrobial drugs rendering complications in the latter stages eventually resulting in death.

The BD MAX Check-Points CPO assay provides detection of the five most common carbapenemase genes in less than 2.5 hours, as compared to traditional methods that can take up to 24 hours. Early detection of patients colonized with these organisms can provide the necessary information to implement proper infection control measures. This assay replaces an earlier version of the test from Check-Points, and offers an improved workflow and an additional target.

John Rossen, Assistant Professor of Medical Microbiology at the University Medical Center, Groningen (UMCG) in the Netherlands and scientific secretary of the ESCMID Study Group for Genomic and Molecular Diagnostics said “This assay has not only improved our turn-around-time, but it also gives us the confidence that we will reduce the risk of transmission and outbreak because patient safety is our number one goal.”

Furthering the league of healthcare-associated infections diagnostic portfolio, BD is seeking to advance health by enhancing medical discovery.